Clinical trial NCT04168957: An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Official title: An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Breastcancer
Lead sponsor: Athenex, Inc.
Sponsor class: INDUSTRY
Collaborators: name: PharmaEssentia
First posted: 2019-11-19
Enrollment: 11
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and who wish to continue Oraxol treatment.

Detailed description: This is a multicenter, open-label, extension study offering the option of further Oraxol treatment to breast cancer patients who have completed the KX-ORAX-007 Oraxol study with complete response (CR), partial response (PR), or stable disease (SD), and who wish to continue further Oraxol treatment. The study contains 3 periods: the Screening Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment.

Eligibility criteria: Inclusion Criteria:

1. Breast cancer patients who have completed Study KX-ORAX-007 without disease progression at Week 16, who wish to continue Oraxol treatment.
2. Signed written informed consent.
3. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days.
4. Patients must be postmenopausal (\>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.

Exclusion Criteria:

1. Have not recovered from unacceptable toxicity associated with previous Oraxol treatment in KX-ORAX-007.
2. Are currently receiving other medications intended for the treatment of their malignancy.
3. Women who are pregnant or breastfeeding.
4. Taking any following prohibited medications:

   * Strong inhibitors (eg, ketoconazole) or strong inducers (eg, rifampin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study).
   * Strong inhibitors (eg, gemfibrozil) or strong inducers (eg, rifampin) of CYP2C8 (within 2 weeks prior to the start of dosing in the study).
   * Strong P-gp inhibitors or inducers.
   * An oral medication with a narrow therapeutic index known to be a P-gp substrate (eg, digoxin, dabigatran) within 24 hours prior to start of dosing in the study.
5. Use of warfarin. Patients receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements.
7. Known allergic reaction or intolerance to study medication components.
8. Known allergic reaction or intolerance to contrast media.
9. Patients who, in the Investigator's opinion, are not suitable for participation in this study.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: From screening until final visit (within 72 hours prior to Day 21 of Study Period 2, preferably before the participant receives any additional chemotherapy)
Secondary outcomes:
measure: Activity: Tumor response
timeFrame: from the start of treatment in KX-ORAX-007 until follow up visit every 2 months after patient withdrawal up to 10 months.
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: Taipei Medical University Shuang Ho Hospital
city: Taichung city
country: Taiwan
facility: China Medical University Hospital
city: Taipei, Taiwan, 11217
country: Taiwan
facility: Taipei Veterans Generla Hospital
city: Taipei
country: Taiwan
facility: Taipei Medical University Hospital
city: Taipei
country: Taiwan
facility: Tr-Service General Hospital
Study officials:
affiliation: Athenex, Inc.
name: David Cutler, MD
role: STUDY_DIRECTOR
References: